Alnylam Pharmaceuticals, Inc.

Biogen Idec Ma Inc.

Dana-farber-cancer Institute Inc.

Biogen Ma Inc.

Other

Biogen, Incorporated

Biogen Idec, Inc.

Curagen Corporation

Victor E Kotelianski

Antonin De Fougerolles

Ellen A Garber

Carl Reid

Kevin Fitzgerald

Akin Akinc

Pamela Tan

Maria Frank-Kamenetsky

Birgit Bramlage

Philip Gotwals

Brian R Bettencourt

Roy R Lobb

Jose William Saldanha

William Querbes

Tatiana Novobrantseva

Alfica Sehgal

Catherine A Hession

William G Kaelin

Herman Van Vlijmen

Cynthia A Green

John P Carulli

Antonin R De Fougerolles

Gregory Hinkle

Antonin DeFougerolles

Greg Hinkle

John Carulli

The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the COL1A1, TGF-&#x3b2;, and SMAD2/3 genes, and methods of using such dsRNA compositions to inhibit expression of COL1A1, TGF-&#x3b2;, and SMAD2/3.

Compositions and methods directed to treating liver fibrosis

The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the PCSK9 gene (PCSK9 gene), comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of the PCSK9 gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier and method for treating diseases caused by PCSK9 gene expression.

Compositions and methods for inhibiting expression of the PCSK9 gene

The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting one or more EGLN genes, EGLN1, EGLN2 and/or EGLN3 and methods of using such dsRNA compositions to inhibit expression of these genes.

Compositions and methods for increasing erythropoietin (EPO) production

A method for the treatment of inflammatory disorders is disclosed, particularly the treatment of arthritis. The method comprises the administration of a function blocking antibody which is capable of binding an epitope of VLA-1.

Method for the treatment of inflammatory disorders

The invention provides antibodies that bind to a plurality of &#x3b2;-chemokines, particularly monocyte chemotactic proteins MCP-1, MCP-2 and MCP-3. The invention also provides cells producing the antibodies, and methods of making and using the same.

Antibodies against monocyte chemotactic proteins

The invention provides humanized antibodies that bind to a plurality of &#x3b2;-chemokines, particularly monocyte chemotactic proteins MCP-1, MCP-2 and MCP-3. The invention also provides therapeutic reagents and methods of treating disorders associated with detrimental MCP activity.

Humanized antibodies against monocyte chemotactic proteins

Methods of treating lupus nephritis using antibodies against monocyte chemotactic proteins

The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the PCSK9 gene (PCSK9 gene), comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of the PCSK9 gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by PCSK9 gene expression and the expression of the PCSK9 gene using the pharmaceutical composition; and methods for inhibiting expression of a PCSK9 gene in a cell.

Growing community of inventors

Boston, MA, United States of America

Victor E Kotelianski